中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

23 records (took 0.023 seconds)

    Albumin binding antibodies and binding fragments thereof
    13.
    发明专利
    Albumin binding antibodies and binding fragments thereof 未知

    公开(公告)号：AU2012335496A1

    公开(公告)日：2014-05-15

    申请号：AU2012335496

    申请日：2012-11-09

    Applicant: UCB PHARMA SA

    Inventor： ADAMS RALPH ,  BHATTA PALLAVI ,  HEYWOOD SAM PHILLIP ,  HUMPHREYS DAVID PAUL

    IPC: C07K16/18 ,  C07K16/28 ,  C07K16/46

    Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.

    ALBUMIN BINDING ANTIBODIES AND BINDING FRAGMENTS THEREOF
    14.
    发明专利
    ALBUMIN BINDING ANTIBODIES AND BINDING FRAGMENTS THEREOF 未知

    公开(公告)号：CA2856216A1

    公开(公告)日：2013-05-16

    申请号：CA2856216

    申请日：2012-11-09

    Applicant: UCB PHARMA SA

    Inventor： ADAMS RALPH ,  BHATTA PALLAVI ,  HEYWOOD SAM PHILLIP ,  HUMPHREYS DAVID PAUL

    IPC: C07K16/18 ,  C07K16/28 ,  C07K16/46

    Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.

    Antibody molecules having specificity for human ox40
    18.
    发明专利
    Antibody molecules having specificity for human ox40 未知

    公开(公告)号：NZ624583A

    公开(公告)日：2015-05-29

    申请号：NZ62458312

    申请日：2012-11-09

    Applicant: UCB PHARMA SA

    Inventor： ADAMS RALPH ,  HUMPHREYS DAVID PAUL ,  BHATTA PALLAVI ,  HEYWOOD SAM PHILIP

    IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/44 ,  C07K16/46

    Abstract: Discloses a bispecific antibody fusion protein which binds human OX40 and human serum albumin comprising: a heavy chain comprising, in sequence from the N-terminal, a first heavy chain variable domain (VH1), a CHI domain and a second heavy chain variable domain (VH2), a light chain comprising, in sequence from the N-terminal, a first light chain variable domain (VL1), a CL domain and a second light chain variable domain (VL2), wherein said heavy and light chains are aligned such that VH1 and VL1 form a first antigen binding site and VH2 and VL2 form a second antigen binding site, wherein the antigen bound by the first antigen binding site is human OX40 and the antigen bound by the second antigen binding site is human serum albumin, wherein the first variable domain of the heavy chain (VH1) comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and the first variable domain of the light chain (Vd) comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3, wherein the second heavy chain variable domain (VH2) has the sequence given in SEQ ID NO:11 and the second light chain variable domain (VL2) has the sequence given in SEQ ID NO: 12 and the second heavy chain variable domain (VH2) and second light chain variable domain (VL2) are linked by a disulphide bond, wherein the sequences are as defined in the complete specification.

Patent Agency Ranking